uploads/2018/02/Neurociences.png

Johnson & Johnson’s Neuroscience Segment in 2017

By

Updated

Neuroscience segment’s revenue trends

In fiscal 2017, Johnson & Johnson’s Neuroscience segment generated revenues of $6.0 billion, which is an ~2.0% decline on a year-over-year (or YoY) basis. In 4Q17, Johnson & Johnson’s Neuroscience segment generated revenues of $1.5 billion, which is ~4.0% growth on a YoY basis.

Article continues below advertisement

Concerta/Methylphenidate: Revenue trends

In 4Q17, JNJ’s Concerta generated revenues of $203.0 million, which reflected an ~0.5% decline on a YoY basis. In 4Q17, in the US market and international markets, Concerta generated revenues of $100.0 million and $103.0 million, respectively.

In fiscal 2017, Concerta reported revenues of $791.0 million, which is an ~8.3% decline on a YoY basis. In 2017, Concerta generated revenues of $384.0 million and $407.0 million, respectively, in the US market and international markets, compared to $486.0 million and $395.0 million in 2016.

Invega Sustenna/Xeplion/Trinza/Trevicta: Revenue trends

In 4Q17, JNJ’s Invega Sustenna generated revenues of $693.0 million, which is ~18.5% growth on a year-over-year (or YoY) basis. In 4Q17, in the US and international markets, Invega Sustenna generated revenues of $436.0 million and $257.0 million, respectively, which reflected ~21.1% and ~14.2% growth on a YoY basis.

In fiscal 2017, Invega Sustenna reported revenues of $2.6 billion, which is ~16.0% growth on a YoY basis. In 2017, in the US market and international markets, Invega Sustenna generated revenues of $1.6 billion and $979.0 million, respectively, which is ~18.4% and ~12.4% growth on a YoY basis.

Article continues below advertisement

Risperdal Consta’s revenue trends

In 4Q17, Risperdal Consta generated revenues of $197.0 million, which is an ~6.2% decline on a YoY basis. In 4Q17, Risperdal Consta generated revenues of $87.0 million and $110.0 million, respectively, in the US market and international markets.

In fiscal 2017, Risperdal Consta reported revenues of $805.0 million, which is an ~10.0% decline on a YoY basis. In 2017, in the US market and international markets, Risperdal Consta generated revenues of $360.0 million and $445.0 million, respectively, compared to $381.0 million and $512.0 million in 2016.

Invega Sustenna and Risperdal Consta are used for the treatment of individuals with schizophrenia. In the schizophrenia marketplace, Johnson & Johnson’s schizophrenia drugs compete with Allergan’s (AGN) Saphris, Eli Lilly’s (LLY) Zyprexa, Otsuka America Pharmaceuticals’ Abilify, and AstraZeneca’s (AZN) Seroquel.

Advertisement

More From Market Realist